Department of Cardiovascular Medicine, Saitama Medical Centre, Jichi Medical University, Saitama, Japan.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Int J Cardiol. 2023 Jun 15;381:45-51. doi: 10.1016/j.ijcard.2023.03.035. Epub 2023 Mar 17.
No study with an adequate patients' number has examined the relationship/overlap between sarcopenia and cachexia. We examined the prevalence of the overlap and prognostic implications of sarcopenia and cachexia in older patients with heart failure using well-accepted definitions.
This was a post-hoc sub-analysis of the FRAGILE-HF study, a prospective, multicenter, observational study conducted at 15 hospitals in Japan. In total, 905 hospitalized older patients were classified into four groups based on the presence or absence of cachexia and/or sarcopenia, which were defined according to the Evans and Asian Working Group for Sarcopenia criteria revised in 2019, respectively. The primary endpoint was 2-year all-cause mortality.
Cachexia and sarcopenia prevalence rates were 32.7% and 22.7%, respectively. Patients were classified into the non-cachexia/non-sarcopenia (55.7%), cachexia/non-sarcopenia (21.7%), non-cachexia/sarcopenia (11.6%), and cachexia/sarcopenia (11.0%) groups. During the 2-year follow-up period after discharge, 158 (17.5%) all-cause deaths (124 cardiovascular deaths [CVD] and 34 non-CVD) were observed. The cachexia/sarcopenia group had the lowest body fat mass and exhibited significantly higher mortality rates (log-rank P < 0.001). Cox proportional hazard analysis revealed that cachexia/sarcopenia was an independent prognostic factor after adjusting for known prognostic factors (versus non-cachexia/non-sarcopenia: hazard ratio, 2.78; 95% confidence interval, 1.80-4.29; P < 0.001). Neither cachexia/non-sarcopenia nor non-cachexia/sarcopenia were significantly associated with all-cause mortality compared with non-cachexia/non-sarcopenia.
Cachexia and sarcopenia are prevalent among older hospitalized patients with heart failure; nonetheless, the overlap is not as prominent as previously expected. The presence of cachexia and sarcopenia is a risk factor for all-cause mortality.
没有足够患者数量的研究检查过肌肉减少症和恶病质之间的关系/重叠。我们使用公认的定义,检查了心力衰竭老年患者中肌肉减少症和恶病质重叠的患病率以及其预后意义。
这是 FRAGILE-HF 研究的事后亚分析,这是一项在日本 15 家医院进行的前瞻性、多中心、观察性研究。共有 905 名住院老年患者根据是否存在恶病质和/或肌肉减少症,按照 2019 年修订的 Evans 和亚洲肌肉减少症工作组标准,分别分为四组。主要终点为 2 年全因死亡率。
恶病质和肌肉减少症的患病率分别为 32.7%和 22.7%。患者分为非恶病质/非肌肉减少症(55.7%)、恶病质/非肌肉减少症(21.7%)、非恶病质/肌肉减少症(11.6%)和恶病质/肌肉减少症(11.0%)组。在出院后 2 年的随访期间,观察到 158 例全因死亡(124 例心血管死亡[CVD]和 34 例非 CVD)。恶病质/肌肉减少症组的体脂肪量最低,死亡率显著更高(对数秩检验 P<0.001)。Cox 比例风险分析显示,在校正已知预后因素后,恶病质/肌肉减少症是独立的预后因素(与非恶病质/非肌肉减少症相比:风险比,2.78;95%置信区间,1.80-4.29;P<0.001)。与非恶病质/非肌肉减少症相比,恶病质/非肌肉减少症或非恶病质/肌肉减少症均与全因死亡率无显著相关性。
肌肉减少症和恶病质在心力衰竭的老年住院患者中较为常见;然而,重叠程度并不像之前预期的那么高。恶病质和肌肉减少症的存在是全因死亡率的一个危险因素。